Optimising hormone therapy in advanced disease

European Urology, Supplements

Volumn 4, Issue 8, 2005, Pages 21-29

  Boccon Gibod, Laurent ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Advanced prostate cancer; Antiandrogen; CAB; IHT; LHRH agonists; PSA DT; PSA relapse; Review; Surgical castration; Timing of therapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MEGESTROL ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ANEMIA; ASTHENIA; BREAST HYPERTROPHY; BREAST TENDERNESS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; ENERGY; FATIGUE; FRAGILITY FRACTURE; GYNECOMASTIA; HEALTH CARE COST; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; META ANALYSIS; METASTASIS; NAUSEA; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING;

EID: 26444462106     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.08.001     Document Type: Article

References (65)

1. F. Debruyne Hormonal therapy of prostate cancer Semin Urol Oncol 20 Suppl 1 2002 4 9
2. J.W. Moul Contemporary hormonal management of advanced prostate cancer Oncol (Huntingt) 12 4 1998 499 505
3. M.A. Khan, and A.W. Partin Management of high-risk populations with locally advanced prostate cancer Oncologist 8 3 2003 259 269
4. L. Boccon-Gibod, A. Bertaccini, A.V. Bono, B. Dev Sarmah, W. Holtl, and N. Mottet Management of locally advanced prostate cancer: a European consensus Int J Clin Pract 57 3 2003 187 194
5. R.A. Zimmerman, and D.J. Culkin Clinical strategies in the management of biochemical recurrence after radical prostatectomy Clin Prostate Cancer 2 3 2003 160 166
6. M.A. Khan, and A.W. Partin Management of patients with an increasing prostate-specific antigen after radical prostatectomy Curr Urol Rep 5 3 2004 179 187
7. S.G. Roberts, M.L. Blute, E.J. Bergstralh, J.M. Slezak, and H. Zincke PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc 76 6 2001 576 581
8. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 6 2000 1632 1642
9. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 17 1999 1591 1597
10. F.H. Schroder Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects BJU Int 83 2 1999 161 170
11. J.F. Ward, M.L. Blute, J. Slezak, E.J. Bergstralh, and H. Zincke The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 5 2003 1872 1876
12. A. Patel, F. Dorey, J. Franklin, and J.B. deKernion Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen J Urol 158 4 1997 1441 1445
13. C.I. Sartor, M.H. Strawderman, X.H. Lin, K.E. Kish, P.W. McLaughlin, and H.M. Sandler Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy Int J Radiat Oncol Biol Phys 38 5 1997 941 947
14. H.M. Sandler, R.L. Dunn, P.W. McLaughlin, J.A. Hayman, M.A. Sullivan, and J.M. Taylor Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy Int J Radiat Oncol Biol Phys 48 3 2000 629 633
15. J.F. Ward, H. Zincke, E.J. Bergstralh, J.M. Slezak, and M.L. Blute Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy J Urol 172 6 Pt 1 2004 2244 2248
16. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 18 2003 1376 1383
17. G. Auclerc, E.C. Antoine, F. Cajfinger, A. Brunet-Pommeyrol, C. Agazia, and D. Khayat Management of advanced prostate cancer Oncologist 5 1 2000 36 44
18. H. Miyamoto, E.M. Messing, and C. Chang Androgen deprivation therapy for prostate cancer: current status and future prospects Prostate 61 4 2004 332 353
19. D.A. Loblaw, D.S. Mendelson, J.A. Talcott, K.S. Virgo, M.R. Somerfield, E. Ben-Josef American Society of Clinical Oncology American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 14 2004 2927 2941
20. G.J. Bubley Is the flare phenomenon clinically significant? Urology 58 2 Suppl 1 2001 5 9
21. P. Iversen, J.E. Johansson, P. Lodding, O. Lukkarinen, P. Lundmo, P. Klarskov Scandinavian Prostatic Cancer Group Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6 J Urol 172 5 Pt 1 2004 1871 1876
22. M.P. Wirth, W.A. See, D.G. McLeod, P. Iversen, T. Morris, K. Carroll Casodex Early Prostate Cancer Trialists' Group Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years J Urol 172 5 Pt 1 2004 1865 1870
23. S.C. Thorpe, S. Azmatullah, G.J. Fellows, J.C. Gingell, and P.J. O'Boyle A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma Eur Urol 29 1 1996 47 54
24. J. Seidenfeld, D.J. Samson, V. Hasselblad, N. Aronson, P.C. Albertsen, and C.L. Bennett Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 7 2000 566 577
25. M.H. Rashid, and U.B. Chaudhary Intermittent androgen deprivation therapy for prostate cancer Oncologist 9 3 2004 295 301
26. N. Bruchovsky, S.L. Goldenberg, M. Gleave, P. Rennie, K. Akakura, and N. Sato Intermittent therapy for prostate cancer Endocr Relat Cancer 4 1997 153 177
27. R. Kurek, H. Renneberg, G. Lübben, E. Kienle, and U.W. Tunn Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer Eur Urol 35 Suppl 1 1999 27 31
28. A. De la Taille, M. Zerbib, S. Conquy, D. Amsellem-Ouazana, N. Thiounn, and T.A. Flam Intermittent androgen suppression in patients with prostate cancer BJU Int 91 2003 18 22
29. N. Bruchovsky, L.H. Klotz, M. Sadar, J.M. Crook, D. Hoffart, and L. Godwin Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related Observations Mol Urol 4 3 2000 191 199
30. D. Prapotnich, N. Cathala, A. Mombet, X. Cathelineau, F. Rozet, and E. Barret Intermittent hormonal therapy for non localized prostate cancer Eur Urol Suppl 4 3 2005 226 (abstract 896)
31. C. Huggins, R.E. Stevens Jr., and C.V. Hodges Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209 223
32. D.G. Mcleod Hormonal therapy: historical perspective to future directions Urology 61 2 Suppl 1 2003 3 7
33. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling, and K. Griffiths Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 5 1991 502 508
34. N.J. Vogelzang, G.W. Chodak, M.S. Soloway, N.L. Block, P.F. Schellhammer, and J.A. Smith Jr. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group Urology 46 2 1995 220 226
35. H. Parmar, L. Edwards, R.H. Phillips, L. Allen, and S.L. Lightman Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer Br J Urol 59 3 1987 248 254
36. E. Bruun, and C. Frimodt-Moller The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group" Scand J Urol Nephrol 30 4 1996 291 297
37. A.V. Schally, A.J. Kastin, and A. Arimura Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies Fertil Steril 22 1971 703 721
38. L.M. Gommersall, D. Hayne, I.S. Shergill, M. Arya, and D.M. Wallace Luteinising hormone releasing hormone analogues in the treatment of prostate cancer Expert Opin Pharmacother 3 12 2002 1685 1692
39. M. Rizzo, T. Mazzei, E. Mini, R. Bartoletti, and P. Periti Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial J Int Med Res 18 Suppl 1 1990 114 125
40. D. Jocham Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results Urol Int 60 Suppl 2 1998 18 24
41. R. Perez-Marreno, F. Chu, D. Gleason, E. Loizides, B. Wachs, and R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 2002 1902 1914
42. F.M. Chu, M. Jayson, M.K. Dineen, R. Perez, R. Harkaway, and R. Tyler A clinical study of 22.5 mg. LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer J Urol 168 2002 1199 1203
43. J.E. Fowler, M. Flanagan, D.M. Gleason, I.W. Klimberg, J.E. Gottesman, R. Sharifi for the VIADUR study Group Evaluation of an implant that delivers Leuprolide for 1 year for the palliative treatment of prostate cancer Urology 55 2000 639 642
44. D. Fontana, M. Mari, A. Martinelli, C. Boccafoschi, C. Magno, and M. Turriziani 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial Urol Int 70 2003 316 320
45. C.F. Heyns, M.P. Simonin, P. Grosgurin, R. Schall, H.C. Porchet for the South African Triptorelin Study Group Comparative efficacy of triptorelin pamoate and Leuprolide acetate in men with advanced prostate cancer BJU Int 92 2003 226 231
46. Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005;(4):30-6.
47. H. Akaza, Y. Homma, K. Okada, M. Yokoyama, N. Moriyama, M. Usami the Prostate Cancer Study Group Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy on naïve localized or locally advanced prostate cancer: a prospective and randomized study Jpn J Clin Oncol 30 2000 131 136
48. E. Kienle, G. Lübben The German Leuprorelin Study Group Efficacy and safety of leuprorelin acetate depot for prostate cancer Urol Int 56 Suppl 1 1996 23 30
49. The Leuprolide Study Group Leuprolide versus diethylstilboestrol for metastatic prostate cancer N Engl J Med 311 1984 1281 1286
50. R. Sharifi, L.D. Knoll, J. Smith, and E. Kramolowsky Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer Urology 51 2 1998 271 276
51. D.C. Bae, and B.S. Stein The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate J Urol 172 6 Pt 1 2004 2137 2144
52. J.L. Peters, A. Fairney, P. Kyd, A. Patel, S. Rogers, and J.J. Webster Bone loss associated with the use of LHRH agonists in prostate cancer Prostate Cancer Prostatic Dis 4 3 2001 161 166
53. Z. Culig, A. Hobisch, G. Bartsch, and H. Klocker Androgen receptor-an update of mechanisms of action in prostate cancer Urol Res 28 4 2000 211 219
54. A. Hobisch, J. Hoffmann, L. Lambrinidis, I.E. Eder, G. Bartsch, and H. Klocker Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model Urol Int 65 2 2000 73 79
55. J.W. Moul, and G. Chodak Combination hormonal therapy: a reassessment within advanced prostate cancer Prostate Cancer Prostatic Dis 7 Suppl 1 2004 S2 S7
56. L.J. Denis Maximal androgen blockade: facts and fallacies Endocr Relat Cancer 5 1998 353 356
57. F. Labrie, A. Dupont, A. Belanger, L. Cusan, Y. Lacourciere, and G. Monfette New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen Clin Invest Med 5 4 1982 267 275
58. E.D. Crawford, M.A. Eisenberger, D.G. McLeod, J.T. Spaulding, R. Benson, and F.A. Dorr A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 7 1989 419 424
59. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients Lancet 346 8970 1995 265 269
60. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 9214 2000 1491 1498
61. D.J. Samson, J. Seidenfeld, B. Schmitt, V. Hasselblad, P.C. Albertsen, and C.L. Bennett Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2 2002 361 376
62. B. Schmitt, C. Bennett, J. Seidenfeld, D. Samson, and T. Wilt Maximal androgen blockade for advanced prostate cancer Cochrane Database Syst Rev 2 2004 CD001526
63. The Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial Br J Urol 79 2 1997 235 246
64. U.E. Studer, D. Hauri, S. Hanselmann, D. Chollet, H.J. Leisinger, and T. Gasser Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88 J Clin Oncol 22 20 2004 4109 4118
65. F.H. Schroder, K.H. Kurth, S.D. Fossa, W. Hoekstra, P.P. Karthaus, M. Debois Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study J Urol 172 3 2004 923 927